Advisors Asset Management Inc. Boosts Stake in DexCom, Inc. (NASDAQ:DXCM)

Advisors Asset Management Inc. raised its position in DexCom, Inc. (NASDAQ:DXCM) by 13.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,800 shares of the medical device company’s stock after buying an additional 1,809 shares during the period. Advisors Asset Management Inc.’s holdings in DexCom were worth $2,053,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Team Hewins LLC grew its position in shares of DexCom by 3.4% during the 1st quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock valued at $354,000 after acquiring an additional 83 shares during the period. Bleakley Financial Group LLC lifted its stake in DexCom by 1.3% in the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock worth $951,000 after purchasing an additional 87 shares in the last quarter. D Orazio & Associates Inc. lifted its stake in DexCom by 0.8% in the 4th quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock worth $1,534,000 after purchasing an additional 93 shares in the last quarter. Gulf International Bank UK Ltd lifted its stake in DexCom by 0.3% in the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock worth $4,448,000 after purchasing an additional 93 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in shares of DexCom by 10.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock valued at $133,000 after buying an additional 98 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several research reports. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Royal Bank of Canada cut their price target on shares of DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a report on Friday. Redburn Atlantic began coverage on shares of DexCom in a research note on Thursday, May 30th. They set a “neutral” rating and a $130.00 target price on the stock. JPMorgan Chase & Co. cut shares of DexCom from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $145.00 to $75.00 in a report on Friday. Finally, Canaccord Genuity Group restated a “buy” rating and set a $145.00 target price on shares of DexCom in a research report on Tuesday, July 23rd. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $113.06.

Insider Transactions at DexCom

In other news, EVP Michael Jon Brown sold 659 shares of DexCom stock in a transaction on Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the transaction, the executive vice president now owns 66,901 shares of the company’s stock, valued at approximately $7,646,115.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, EVP Michael Jon Brown sold 659 shares of DexCom stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the sale, the executive vice president now owns 66,901 shares in the company, valued at approximately $7,646,115.29. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the sale, the director now owns 25,349 shares of the company’s stock, valued at approximately $2,878,378.95. The disclosure for this sale can be found here. Insiders sold 4,112 shares of company stock valued at $480,861 in the last 90 days. 0.30% of the stock is currently owned by insiders.

DexCom Stock Performance

Shares of DexCom stock opened at $64.00 on Friday. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The firm has a market capitalization of $25.45 billion, a P/E ratio of 41.29, a P/E/G ratio of 1.57 and a beta of 1.16. The firm’s 50 day moving average is $115.28 and its two-hundred day moving average is $123.79. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. DexCom had a return on equity of 32.27% and a net margin of 16.95%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter last year, the company earned $0.34 earnings per share. DexCom’s quarterly revenue was up 15.3% compared to the same quarter last year. Research analysts forecast that DexCom, Inc. will post 1.76 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.